Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Study examines side effects observed with SMA gene therapy

Serious side effects that can cause or prolong hospital stays occurred frequently among children with spinal muscular atrophy (SMA) who are receiving treatment with the gene therapy Zolgensma (onasemnogene abeparvovec-xioi), a new study of real-world safety data highlights. Specifically, according to the researchers, more than half of all…

MDA 2024: Spinraza may benefit some SMA children after Zolgensma

In children with spinal muscular atrophy (SMA) who have a less-than-optimal response to the gene therapy Zolgensma (onasemnogene abeparvovec-xioi), subsequent treatment with Spinraza (nusinersen) can improve motor function and may reduce nerve damage. That’s according to interim data from the Phase 4 RESPOND study (NCT04488133),…